LENZ Therapeutics specializes entirely in the discovery, development, and commercialization of advanced ophthalmic pharmaceutical solutions targeting common degenerative vision conditions. Its primary scientific and commercial focus centers on treating presbyopia—the age-related loss of near-focus ability—through targeted, pupil-selective pharmacological innovations designed to enhance patient quality of life without invasive surgical interventions.